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Background-—Coronary artery disease (CAD) outcomes consistently improve when they are routinely measured and provided back
to physicians and hospitals. However, few centers around the world systematically track outcomes, and no global standards exist.
Furthermore, patient-centered outcomes and longitudinal outcomes are under-represented in current assessments.
Methods and Results-—The nonproﬁt International Consortium for Health Outcomes Measurement (ICHOM) convened an
international Working Group to deﬁne a consensus standard set of outcome measures and risk factors for tracking, comparing, and
improving the outcomes of CAD care. Members were drawn from 4 continents and 6 countries. Using a modiﬁed Delphi method,
the ICHOM Working Group deﬁned who should be tracked, what should be measured, and when such measurements should be
performed. The ICHOM CAD consensus measures were designed to be relevant for all patients diagnosed with CAD, including
those with acute myocardial infarction, angina, and asymptomatic CAD. Thirteen speciﬁc outcomes were chosen, including acute
complications occurring within 30 days of acute myocardial infarction, coronary artery bypass grafting surgery, or percutaneous
coronary intervention; and longitudinal outcomes for up to 5 years for patient-reported health status (Seattle Angina Questionnaire
[SAQ-7], elements of Rose Dyspnea Score, and Patient Health Questionnaire [PHQ-2]), cardiovascular hospital admissions,
cardiovascular procedures, renal failure, and mortality. Baseline demographic, cardiovascular disease, and comorbidity information
is included to improve the interpretability of comparisons.
Conclusions-—ICHOM recommends that this set of outcomes and other patient information be measured for all patients with CAD.
( J Am Heart Assoc. 2015;4:e001767 doi: 10.1161/JAHA.115.001767)
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C ardiovascular disease represents the single greatestglobal disease burden, both in mortality and morbidity.1
Recent alarming increases in incidence noted in low-income
and middle-income countries raise concern for future gener-
ations.2 However, increasing cardiovascular disease burden is
not inevitable. High-income nations have invested heavily in
addressing this problem. Mortality from cardiovascular dis-
ease, especially coronary artery disease (CAD), has dramat-
ically decreased in the past few decades.3,4 While public
health initiatives aimed at primary prevention have certainly
led to some of these gains, advances in treatment for patients
with CAD have accounted for a signiﬁcant portion.5,6
Despite overall improvement in high-income countries,
signiﬁcant variation in outcomes for patients with CAD still
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exists. Signiﬁcant differences in 30-day mortality following
acute myocardial infarction (AMI) have been found between
the United Kingdom and Sweden.7 Even among elderly
patients admitted for AMI within the United States, a greater
than twofold difference in 30-day risk standardized mortality
was found, depending on which hospital provided the care.8
These ﬁndings suggest an opportunity to identify the best
management practices that lead to optimal outcomes and
then to implement them across broad populations, lessening
the global burden of cardiovascular disease.
Cardiovascular registries have been operating worldwide for
several decades in large part to accomplish these goals,9,10 and
impressive gains in quality of care and outcomes have been
made.11–13 However, the full potential impact of cardiovascular
registries is currently constrained by the lack of 2 key factors:
international standard deﬁnitions and longer-term patient-
centered outcomes. With the notable exception of collabora-
tions in the United State between the American College of
Cardiology and the Society of Thoracic Surgeons registries,
most cardiovascular registries have developed in isolation, and
they rarely cross national borders. This approach has led to
registries tracking different outcomes and/or using different
deﬁnitions for equivalent outcomes. This lack of standard
outcomes and deﬁnitions has limited the validity of interna-
tional comparisons across providers of different health sys-
tems. Educational and quality improvement activities have
remained primarily local or regional, and the wider variation in
care and outcomes globally has remained unaddressed. In
addition, cardiovascular registries have focused primarily on
improving quality of care by reporting process measures and
short-term outcomes, most commonly tracking in-hospital or
30-daymortality and complications. Longer-term outcomes (for
example, after 1 and 5 years), and patient-centered outcomes
(for example, angina burden, functional status, and health-
related quality of life), more closely reﬂect the ultimate beneﬁt
of care but are rarely tracked in real-world settings. Hence, the
true value of individual interventions and of whole systems of
health care is never fully understood.
To align outcome measurement efforts globally and to
promote more comprehensive measurement of outcomes, the
nonproﬁt International Consortium for Health Outcomes
Measurement (ICHOM)14 formed a CAD working group.
ICHOM was founded in 2012 by Harvard Business School,
The Boston Consulting Group, and The Karolinska Institutet
and has so far completed 11 other standard sets of outcomes.
It is funded through support from the founders and from a
wide range of international sponsoring partners. In accor-
dance with the goals of ICHOM, the CAD Working Group
aimed to deﬁne a parsimonious, consensus, standard set of
outcomes that are meaningful to patients with CAD and are
able to be tracked for an appropriate length of time across
diverse health systems.
Methods
Objectives
The primary goal of this initiative was to identify a parsimo-
nious, consensus, set of outcomes with standard deﬁnitions
for patients with CAD that could be tracked by health systems
and clinical registries around the world. In particular, this
standard set would encompass a range of outcomes relating
to mortality, morbidity, and patient health status (ie, symp-
toms, functional status, and health-related quality of life). The
use of a standard set of outcome measurements would not
preclude any system or registry collecting and reporting
additional measures as desired. A secondary goal was to
identify a standard set of variables to be systematically
collected to enable case-mix adjustment, which would support
comparison of CAD outcomes among providers and health
systems with different case mixes of patients.
Composition of Working Group
ICHOM brought together an internationally recognized group
of clinician and nonclinician leaders in the ﬁeld of CAD with
expertise in (1) clinical trials and registries, (2) public and
private health system management, (3) patient-centered
outcomes research, (4) outcomes measurement, (5) quality
improvement, and (6) patient advocacy. There were a total of
17 members from 4 continents and 6 countries. ICHOM also
formed a project team, which consisted of a project leader
(C.J.S., then T.A.K.), who coordinated the process and a
research fellow (E.S.S.), a cardiologist who provided subject-
speciﬁc expertise.
Process
A modiﬁed Delphi technique was used to develop consensus
around all major decision areas, including the scope of the
population to be covered, the minimum outcome set, and the
risk factors required for case-mix adjustment. Consistent with
this method, a combination of teleconferences and surveys
was used to forge consensus. Between December 2012 and
November 2013, the Working Group participated in 11
conference calls, 10 of which were followed by surveys on
key decision points. Prior to each teleconference, the ICHOM
project team developed an agenda, listed key proposals, and
summarized relevant evidence from the literature. The
Working Group reviewed these documents in advance and
discussed them during each teleconference.
The Working Group selected outcomes based on 4 criteria:
(1) the frequency of the outcome; (2) its impact on the patient;
(3) the potential to modify the outcome; and (4) the feasibility
of “capturing” the outcome in clinical practice. Additional
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criteria for patient-reported outcome measures (PROMs)
included (1) the domain coverage; (2) the psychometric
properties; (3) the feasibility to implement; and (4) the clinical
interpretability. Next, time points for data collection were
selected for each outcome. Risk-adjustment variables were
selected based on 3 criteria: (1) the relevance (strength of the
causal linkage between the risk factor and the outcome), (2) the
risk factor independence, and (3) feasibility of measurement.
Following each call, the ICHOM team circulated detailed
minutes and an electronic survey on each key decision point.
Decisions were ﬁnalized when more than two thirds of the
Working Group members concurred. In cases where consen-
sus was not achieved, further discussion ensued during
subsequent teleconferences, which was followed by a second
survey. The ﬁnal standard set was approved unanimously by
all members of the Working Group.
Results
Cohort Deﬁnition
As deﬁned by the CAD Working Group, the target population
is all patients with CAD, including patients presenting with any
of the following qualifying diagnoses, test ﬁndings, or
interventions: angina, acute coronary syndrome, AMI, CAD
noted on angiography or other coronary imaging modalities
(eg, computed tomography; magnetic resonance imaging),
stress testing suggestive of CAD, percutaneous coronary
intervention (PCI), or coronary artery bypass grafting (CABG).
Informing the Working Group’s approach to cohort selection
was the recognition that the same set of longitudinal
outcomes (eg, survival, symptoms, and quality of life) was
relevant to all patients with CAD, regardless of disease state
or treatment received, while additional treatment and event-
speciﬁc outcomes could be described for patients experienc-
ing AMI or undergoing PCI or CABG. In addition, the Working
Group decided that the outcomes should be assessed at
particular times after initial diagnosis and from each major
event (AMI, PCI, and CABG).
Outcomes
The CAD Working Group decided to focus on both short-term
(hospitalization, 30 days posthospitalization) and long-term (1
year and 5 years from ﬁrst enrollment) outcomes (Figure). To
inform its work, the Working Group reviewed the outcome
A
B
Figure. A, Example timeline for a patient diagnosed with asymptomatic CAD without any subsequent events. B, Example timeline for a patient
initially diagnosed at time of an AMI and who subsequently undergoes a PCI one and a half years later. A new revascularization procedure or a
new diagnosis of AMI constitutes a new index event, and tracking of PROMs should reset from this point, tracking again at 30 days, and then
annually for 5 years. Given that longitudinal outcomes are obtained from administrative data, they are collected for both the entry event (eg,
AMI) and the new event (eg, PCI). AMI indicates acute myocardial infarction; CAD, coronary artery disease; PCI, percutaneous coronary
intervention; PROMs, patient-reported outcome measures.
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domains, relevant deﬁnitions, and methods of ascertainment
used in 13 established registries (Table 1). However, as these
registries mainly report outcomes occurring during index
hospitalizations and do not include patient-reported out-
comes, the CAD Working Group proposed additional timelines
for outcome measurement as well as collection of a set of
PROMs.
Survival
The Working Group unanimously agreed to assess survival at
30 days postdischarge, and at 1 and 5 years following cohort
entry. While longer follow-up is clearly important to patients, it
may be less feasible for health systems to capture. Nonethe-
less, for the 3 selected time periods, the CAD Working Group
decided to assess all-cause mortality using death registers.
Limitations of such death registries were discussed, including
the expense and time lag involved in obtaining these data.
Additionally, in some countries, access to death registers is
limited; in such circumstances, ICHOM will advocate that
governments make these data more available. Disease-
speciﬁc mortality was not selected as it is less meaningful
to patients than all-cause mortality; additionally, the validity of
the data may be limited if cause of death is not clinically
adjudicated.
Longitudinal Outcomes
The CAD Working Group focused on longitudinal outcomes of
CAD that are frequent, that are associated with a high
morbidity (affecting patients’ quality of life and functional
status), and that are costly. It elected to measure outcomes at
1 and 5 years from cohort entry. Patients who experience a
cardiovascular event (eg, AMI) or undergo a cardiac procedure
(PCI or CABG) during the follow-up period will not be
censored; rather, they will continue to be followed for the
entire 5-year period from the time they entered the cohort.
However, they will also be included in a second cohort with an
additional 5 years of follow-up from the new index event or
procedure. The CAD Working Group elected to include the
following outcomes, representing CAD progression and com-
mon, high-impact health outcomes related to cardiovascular
disease: all-cause mortality (from death registers); AMI,
revascularization procedures (PCI or CABG); new hospitaliza-
tions for acute coronary syndrome, heart failure, hemorrhagic
and/or ischemic stroke; and advanced renal failure (detected
as a new requirement for dialysis). It was decided not to
include peripheral artery disease as an outcome as there is
substantial international variation in detection of peripheral
artery disease, depending on the intensity of diagnostic
practices and therapeutic capacities.
The CAD Working Group decided to restrict longitudinal
outcomes to those that could be captured via administrative
data, as most current registries and electronic health record
databases are not designed to capture events occurring
outside of the acute care episode. It was recognized that for
many countries without a single-payer healthcare system or
an all-payer claims database, long-term outcomes can be
difﬁcult to ascertain. Therefore, linking of clinical data with
administrative data was felt to be the most feasible and
least resource-intense approach to collecting long-term
outcomes.
Table 1. Registries Reviewed to Inform Outcome and Risk Factor Domains and Deﬁnitions
Country Registry Name Reference
Australia Coronary Angiogram Database of South Australia (CADOSA) 15
Singapore Singapore Myocardial Infarct Registry 16
Spain (Catalonia) Codi Infarct Registry 17
Sweden Swedeheart: Heart Surgery Registry 18
Sweden Swedeheart: Swedish Coronary Angiography and Angioplasty Registry (SCAAR) 18
Sweden Swedeheart: Swedish Register of Cardiac Intensive Care (RIKS-HIA) 18
Sweden Swedeheart: Swedish Secondary Prevention Registry (SEPHIA) 18
United Kingdom Myocardial Ischemia National Audit Project (MINAP) 19
United Kingdom British Cardiovascular Intervention Society National PCI Audit 20
United Kingdom Society for Cardiothoracic National Adult Cardiac Surgery Audit 21
United States NCDR ACTION Registry—GWTG 22,23
United States NCDR CathPCI Registry 22,23
United States Society of Thoracic Surgeons National Database: Adult Cardiac 24
GWTG indicates Get With The Guidelines; NCDR, National Cardiovascular Data Registry.
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Patient-Reported Health Status
PROMs are increasingly recognized as providing valuable
information about health-related quality of life and are guiding
more informed discussions about care management. A review
of existing PROMs used in describing cardiovascular disease
revealed 3 main instruments, speciﬁcally, the Seattle Angina
Questionnaire25 (SAQ-7), Rose Dyspnea Score,26 Patient
Health Questionnaire27 (PHQ-2), Quality of Life Index28 (QLI)
Cardiac Version IV, and Quality of Life after Myocardial
Infarction (QLMI-2/MacNew).29 These instruments measure
cardiac-related symptoms (eg, shortness of breath, chest pain),
functional status, and quality of life. The Working Group
considered the above measurement tools based on the
following qualities: domain coverage (symptom burden, func-
tional status, and quality of life), psychometric properties
(validity, sensitivity, and quality of life), feasibility to implement
(length of questionnaire, language availability, and cost to
implement), and clinical interpretability (knowledge of how to
interpret scores in a clinically meaningful way). The SAQ-7,
which is short, widely translated intomany languages, and has a
high degree of clinically interpretability most closely aligned
with these qualities and was recommended in the standard set.
The Working Group desired additional questions to assess
patients’ levelofdyspneaanddepressive symptoms.ThePHQ-2,
a widely used 2-item questionnaire assessing signs of depres-
sion, and 2 items from theRoseDyspnea Scorewere included to
cover these domains. The Working Group also desired but did
not reach a consensus on including time to return to normal
activities, return to work, sexual function, or medication side
effects within the Standard Set, primarily due to a lack of
standardized assessments. The setwill evolve over time, andwe
anticipate these factors may be included in the future.
Complications
In addition to survival, longitudinal outcomes, and patient-
reported health status, the Working Group voted to measure
complications following PCI and CABG procedures that can
have a signiﬁcant impact on patients’ quality of life and health
outcomes, and that can enable comparison of providers’ and
institutions’ technical quality of care. Based on registries from
the Society for Thoracic Surgeons and the National Cardiovas-
cular Data Registry, the Working Group selected several
periprocedural outcomes for inclusion in the standard set.
These outcomes include stroke, renal failure, and length of stay
(for patients undergoing PCI and CABG); prolonged ventilation,
sternal wound infections, and reoperations (for patients
undergoing CABG only); and coronary dissection/perforation,
emergent CABG, and vascular complications (for patients
undergoing PCI only) (Table 2). The Working Group excluded
conditions that were considered to be particularly rare, variably
detected depending on intensity of care, and difﬁcult to
diagnose, (eg, periprocedural MI [variable detection; unclear if
clinically meaningful], cardiac tamponade [rare]; restenosis rate
[variable detection]; pneumonia among patients undergoing
CABG [often not distinguishable from atelectasis]; and deep
venous thrombosis among patients with CABG [rare]).
Case-Mix Adjustment
The Working Group was tasked with deﬁning a minimum set of
risk factors that would qualify as candidate variables for case-
mix adjustment of both clinical and patient-reported outcomes.
Risk factors common to all CAD patients were deﬁned aswell as
add-on variables for patients with AMI, PCI, and CABG (Table 3).
The intent was to highlight factors that every health system
should be collecting using a standard deﬁnition to enable
comparisons across health systems. Informing the selection of
risk factors was a review of existing riskmodels commonly used
to assess severity of illness and prognosis (eg, the GRACE
model30; TIMI risk score31) as well as assessing the impact that
a speciﬁc risk factor has on the outcomes in our set, based on
the literature and expertise of the Working Group. Of note,
socioeconomic status and psychosocial factors were not
included due to the difﬁculty of standardizing these variables
in the international setting and the lack of consensus regarding
adjusting for these variables in risk models. The set of
covariates is not intended to be exhaustive but will serve as a
basis of developing international risk models for adjusting
outcome performance across institutions.
Data Collection
A very important long-term goal of this effort is to produce
data that can be easily compared between providers, centers,
and countries. To achieve this, we recommend processes to
reduce variability including the use of similar data sources,
recognizing that the speciﬁc details of data collection will
necessarily differ by center. As outlined in Tables 2 and 3, the
potential sources include administrative data and death
registries, patient-reported sources, and clinical abstraction
or physician-reported sources, and we recommend that the
source of data as well as the response rate (if patient
reported) be tracked for every measure. A data collection
manual that further describes each measure, its deﬁnition,
inclusion and exclusion criteria, and potential data sources is
available on the ICHOM web site (http://www.ichom.org/
project/coronary-artery-disease/).
Discussion
The ICHOM CAD Working Group identiﬁed a consensus
standard set of outcomes for the spectrum of patients with a
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diagnosis of CAD in order to provide a foundation for making
appropriate comparisons among countries and health sys-
tems in efforts to improve quality.32 The set incorporates
frequently unreported outcomes that are important to
patients, such as symptom burden and quality of life, as well
as traditional outcomes such as mortality and periprocedural
complications. The Working Group recommended not only
short-term in-hospital outcomes but longer-term (1- and 5-
year) outcomes. As appropriate comparison of outcomes
requires robust risk adjustment, this set also includes
baseline patient demographic and clinical information. To
our knowledge, this is the ﬁrst coordinated, multinational
effort to recommend a standard set of outcomes that all
health systems should aspire to collect.
Deﬁning value in health care and sharing data across
health systems will require standard deﬁnitions of outcomes
and patient characteristics.32 Well-designed and implemented
standardized registries have attempted to ﬁll this void and
have provided the foundation for quality improvement in CAD
in many countries.11–13 However, there have been few
international comparisons outside of selected populations
within clinical trials. Recent investigations into treatment
patterns33 and outcomes7 have shed some light but are
limited to select countries with well-developed registries. Even
Table 2. Summary of Standard Set of Outcomes for Patients With Coronary Artery Disease
Category (Cohorts) Measure Details Timing Data Source
Longitudinal
outcomes (All)
All-cause mortality Date of death Tracked for 5 years after index
event—reported at 1 and 5 years
Administrative
Admissions (for AMI,
hemorrhagic stroke,
ischemic stroke or
heart failure)
Date of each admission & discharge
Procedural interventions Date of PCI and/or CABG
Acute renal failure New requirement for dialysis
Patient- reported
health status (All)
Angina, dyspnea,
depression, functional
status, health-related
quality of life
SAQ-7, PHQ-2, Rose Dyspnea 30 days+then annually to 5 years
after index event
Patient reported
Acute complications
of treatment
(PCI & CABG)
Mortality post procedure Date of death Within index hospitalization+within
30 days of procedure
Clinical or
administrativePlace of death Options: Home; acute care hospital
or rehab; nursing home or hospice
Stroke and stroke type Ischemic; hemorrhagic; unknown
Acute renal failure New requirement for dialysis
Total length of stay Date at arrival and discharge Within index hospitalization
Post-procedure
length of stay
Date of intervention and discharge
Major surgery
complications
(CABG only)
Prolonged ventilation Mechanical ventilation >24 h
post-surgery
Within index hospitalization Clinical
Deep sternal wound infection Requires operative intervention,
positive culture & antibiotics
Within index hospitalization+within
30 days of procedure
Reoperation required Return to operating theatre (for other
than wound)
Interventional
cardiology
complications
(PCI only)
Significant dissection Type C to F dissections Within index hospitalization Clinical
Perforation Angiographic or clinical evidence of
perforation
Emergent CABG for failed PCI Emergency cardiothoracic surgery
Vascular complications
requiring intervention
At percutaneous entry site Within index hospitalization+within
30 days of procedure
Bleeding event within 72 h Within 72 h of PCI Within index hospitalization+within
72 h of procedure
The full list of deﬁnitions is available on the website (http://www.ichom.org/project/coronary-artery-disease/). AMI indicates acute myocardial infarction; CABG, coronary artery bypass
grafting; PCI, percutaneous coronary intervention; PHQ-2, Patient Health Questionnaire; SAQ-7, Seattle Angina Questionnaire.
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within these comparisons, subtle but potentially important
differences exist in deﬁnitions for patient clinical character-
istics and outcomes. Key data elements and deﬁnitions for
measuring outcomes among patients with CAD have been put
forth from the European Union34 and the American Heart
Association/American College of Cardiology.35 The current
effort supports the principles of these initiatives, taking into
consideration the different health systems and different data-
collecting capabilities across the globe. In this way, valid
comparisons will be feasible across a wider practice variation
than found within a single country in the hope of improving
quality of care for a broader population. In addition, interna-
tional registry-based randomized clinical trials will become
more feasible.
Notably, the current set emphasizes outcomes that aremost
important to patients, including PROMs. The “patient voice” has
often been neglected in clinical registries and quality improve-
ment efforts,36,37 but awareness of its importance is
Table 3. Summary of Standard Set of Risk Factors for Patients With Coronary Artery Disease
Timing for Collection Measure Details Data Source
First contact with hospital
services (eg, outpatient clinic
or emergency department)
Age Date of birth Administrative, patient
reported, or clinicalSex Sex at birth
Height Documented Clinical
Weight Documented
Previous AMI Documented in history
Heart Failure Documented in history
Hypertension Documented in history
Stroke Documented in history
Diabetes Documented in history
Insulin dependence Documented in history
Peripheral arterial disease Documented in history
Chronic lung disease Documented in history
Liver cirrhosis Documented in history
Dementia Documented in history
Dialysis dependent Documented in history
Baseline creatinine Documented in history
At time of presentation with
AMI or at time of PCI or CABG
Cardiogenic shock At first medical contact
Cardiac arrest Prehospital or in ED
Creatinine First measurement for AMI or last
measurement prior to PCI or CABG
At time of presentation with AMI Troponin Troponin T or I, lab’s upper limit of normal
Heart rate First measurement for episode of care
Systolic blood pressure First measurement for episode of care
Type of AMI NSTEMI or STEMI
At time of PCI or CABG Procedure Status Including elective, urgent, emergent, emergent
salvage
Left main disease ≥50% compromise of vessel diameter or 30%
–50% with an FFR <0.75 or a minimum
lumen area <6 mm2 or a minimum lumen
diameter <2.8 mm
Number of diseased vessels ≥50% narrowing of any vessel preoperatively,
left main disease counted as 2 vessels
Previous CABG/PCI Including date of procedure
The full list of deﬁnitions is available in a Reference Guide on the International Consortium for Health Outcomes Measurement web site (http://www.ichom.org/project/coronary-artery-
disease/). AMI indicates acute myocardial infarction; CABG, coronary artery bypass grafting; ED, emergency department; FFR, fractional ﬂow reserve; NSTEMI, non-ST-segment elevation
myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
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increasing.38 The American Heart Association recently released
a scientiﬁc statement advocating for patient-reported health
status as a measure of cardiovascular health.39 Understanding
that collecting PROMs will place an increased burden of
collection in most current practice settings, the working group
recommends a parsimonious group of well-validated PROMs to
efﬁciently cover the 3main components of patient health status
—symptom burden, functional status, and health-related
quality of life—by using elements of the SAQ-7,25 Rose
Dyspnea Score,26 and PHQ-2.27
Current outcome assessments frequently are conﬁned to
shorter-term, often in-hospital, outcomes. When collected,
longer-term outcomes are usually limited to mortality or a
narrow list of events, such as myocardial infarctions, inter-
ventions, or surgical procedures. While important and rela-
tively easy to obtain, these outcomes do not represent the full
time horizon of health experience important to patients.
Signiﬁcant differences have been found evaluating hospital
performance depending on the use of in-hospital mortality or
30-day mortality.40 Longer-term outcomes, including assess-
ments at 1 and 5 years after events or treatment, would
provide a clearer picture and a more appropriate basis for
comparing different strategies and health systems. However,
the implementation of these longer-term outcomes will
present challenges that will need to be periodically assessed.
A unique strength of this effort was the diversity of the
CAD Working Group members, which included a patient
representative as well as physician leaders from around the
world, including middle-income countries. All shared in
common signiﬁcant expertise in outcomes measurement,
quality improvement, and policy. The Working Group mem-
bers’ unique, global perspectives were critical to informing the
minimum standard outcomes set. While teleconferences were
oriented around current literature and practices, the members
shared their own country or health system’s current efforts
and challenges to implementing outcomes measures. Having
designed this set, the CAD Working Group has elected a
steering committee to oversee its continual iteration to reﬂect
changes in data collection capacity, to clarify outcome and
patient characteristic deﬁnitions as needed, and to respond to
any improvements in outcome assessment. In particular,
outcomes such as return to daily activities, productivity, and
medication or device safety signals were not included in this
set. Although acknowledged as important, these outcomes
were not included in the initial minimum standard set due to
the need for further investigation into how best to standardize
assessment.
We recognize that implementation of a globally stan-
dardized set of indicators will not be easy. Key implemen-
tation barriers to overcome include (1) infrastructure cost
to collect patient-reported outcomes, (2) linkages with
longitudinal administrative data sources, (3) streamlining
clinician data collection within electronic health records,
and (4) aligning existing registries and data-collection
efforts to map to the global ICHOM standard. The near-
term goal will be to partner with pioneering provider
institutions, including selected members of this Working
Group, to implement all or part of the set and to use this
as a proof of concept towards broader adoption in
registries as well as endorsement by payers and govern-
ments. In this way, we can move in a step-by-step fashion
towards our ultimate goal—internationally comparable data
on patient-centered outcomes.
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